Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.
5Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.